These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 29727385

  • 1. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
    Varakanahalli S, Sharma BC, Srivastava S, Sachdeva S, Dahale AS.
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M, Peck-Radosavljevic M, König F, Mittermaier C, Gangl A, Ferenci P.
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [Abstract] [Full Text] [Related]

  • 3. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P, Sharma BC, Agrawal A, Sarin SK.
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Stauch S.
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [Abstract] [Full Text] [Related]

  • 7. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV, Sharma BC, Sharma P, Sarin SK.
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [Abstract] [Full Text] [Related]

  • 8. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Sharma BC, Sharma P, Agrawal A, Sarin SK.
    Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S, Jafri W, Mumtaz K, Islam M, Abbas Z, Shah HA, Hamid S.
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis.
    Ampuero J, Simón M, Montoliú C, Jover R, Serra MÁ, Córdoba J, Romero-Gómez M.
    Gastroenterology; 2015 Nov; 149(6):1483-9. PubMed ID: 26299413
    [Abstract] [Full Text] [Related]

  • 12. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF, McPhail MJW.
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [Abstract] [Full Text] [Related]

  • 13. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
    Bai M, Yang Z, Qi X, Fan D, Han G.
    J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
    Hass HG, Nägele T, Seeger U, Hösl F, Gregor M, Kaiser S.
    Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
    [Abstract] [Full Text] [Related]

  • 17. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
    Bai M, He C, Yin Z, Niu J, Wang Z, Qi X, Liu L, Yang Z, Guo W, Tie J, Bai W, Xia J, Cai H, Wang J, Wu K, Fan D, Han G.
    Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
    [Abstract] [Full Text] [Related]

  • 18. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
    Ndraha S, Simadibrata M.
    Acta Med Indones; 2010 Jul; 42(3):158-61. PubMed ID: 20724770
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
    Jhajharia A, Singh S, Jana S, Ashdhir P, Nijhawan S.
    Sci Rep; 2024 May 24; 14(1):11862. PubMed ID: 38789596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.